Advertisement

Topics

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

14:32 EST 13 Nov 2017 | SCRIP

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival regardless...

      

Related Stories

 

Original Article: Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

NEXT ARTICLE

More From BioPortfolio on "Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...